Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
Sponsor: Therini Bio Pty Ltd
Summary
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
Official title: A Phase 1b Open-Label, Multiple Ascending Dose Study of the Safety, Tolerability, and Biological Activity of Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2024-12-18
Completion Date
2026-02-28
Last Updated
2024-12-19
Healthy Volunteers
No
Interventions
THN391 MAD
Route of administration- IVT injection
Locations (2)
Marsden Eye Specialists
Parramatta, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia